In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kimberly-Clark Corp.

http://www.kimberly-clark.com

Latest From Kimberly-Clark Corp.

FDA Guidance On Transitioning COVID-19 EUA Products Has US Firms Watching The Clock

Stakeholders across medtech industry submit comments on FDA's itsplans to help companies looking to keep their EUA products on the market post-pandemic.

Coronavirus COVID-19 Guidance Documents

Brand-Blinding Needed In Comparison Studies, WaterWipes Told In Review Of Baby Wipe Claim

NAD says firm's superiority and establishment claims should be removed from marketing. WaterWipes relied on results from “Baby Skin Integrity Comparison Survey” published in Journal of Pediatrics and Neonatology, but NAD agreed with challenger Kimberly-Clark that not blinding the brands from study subjects weakened the results.

Advertising, Marketing & Sales Regulation

Market Intel: Insulin Pumps Dominate $7bn-Plus Global Infusion Devices Market

The global infusion drug delivery market continues to be driven by the rising prevalence of chronic disease and associated obesity, coupled with a growing aging population. Technological advancements such as less invasive pumps, needlestick prevention features and miniaturization have also supported the growing demand, but obstacles such as safety and security issues remain. According to a new report by Meddevicetracker, the global market for infusion pumps and disposables will reach $9.9bn by 2022, a CAGR of 6.4% from 2017. This article takes an in-depth look at the overall infusion pumps market, and dives deeper into the three fastest-growing segments – insulin, enteral and disposable pumps – highlighting the key players and competitive landscape.

Metabolic Market Intelligence

Device/Diagnostics Quarterly Deal-Making Statistics, Q4 2017

Device fundraising during the fourth quarter totaled $2.6 billion, making it the strongest quarter of the year. Q4 M&A activity reached $3.9 billion, higher than Q3's $3.4 billion, but still one of the lowest quarters of the year. Both fourth quarter diagnostics financings and M&As hit an all-year low of $622 million, and $2.8 million, respectively.

Deals Market Intelligence
See All

Company Information

  • Industry
  • Diversified
  • Pharmaceuticals
    • OTC, Consumer
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
UsernamePublicRestriction

Register